Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats

Toxicology Letters

Volumn 213, Issue 3, 2012, Pages 332-344

  Lee, Eun Young ^a   Lee, Jeong Eun ^a   Park, Jae Hyeon ^a   Shin, In Chul ^a   Koh, Hyun Chul ^a  

^a Hanyang University   (South Korea)

Author keywords

6 OHDA; Astrocyte; Cyclooxygenase 2; Peroxisome proliferator activated receptor ; Tyrosine hydroxylase

Indexed keywords

CYCLOOXYGENASE 2; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; OXIDOPAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN DEGENERATION; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG MECHANISM; MALE; MICROGLIA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA;

ANIMALS; BASAL GANGLIA; CALCIUM-BINDING PROTEINS; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; GLIAL FIBRILLARY ACIDIC PROTEIN; INJECTIONS, INTRAPERITONEAL; MALE; MICROFILAMENT PROTEINS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; THIAZOLIDINEDIONES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE 3-MONOOXYGENASE;

RATTUS;

EID: 84865320274     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.07.016     Document Type: Article

References (64)

1. Akiyama H., McGeer P.L. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Research 1989, 489:247-253.
2. Akula K.K., Dhir A., Kulkarni S.K. Rofecoxib a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism. Epilepsy Research 2008, 78:60-70.
3. Ambrosi G., Armentero M.T., Levandis G., Bramanti P., Nappi G., Blandini F. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. Brain Research Bulletin 2010, 82:29-38.
4. Barreto G.E., Gonzalez J., Torres Y., Morales L. Astrocytic-neuronal crosstalk: implications for neuroprotection from brain injury. Neuroscience Research 2011, 71:107-113.
5. Bennett D.A., Beckett L.A., Murray A.M., Shannon K.M., Goetz C.G., Pilgrim D.M., Evans D.A. Prevalence of parkinsonian signs and associated mortality in a community population of older people. New England Journal of Medicine 1996, 334:71-76.
6. Bernardo A., Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Current Pharmaceutical Design 2006, 12:93-109.
7. Bernardo A., Minghetti L. Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Research 2008, 2008:1-10.
8. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. Journal of Neurochemistry 2002, 82:615-624.
9. Carta A.R., Frau L., Pisanu A., Wardas J., Spiga S., Carboni E. Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience 2011, 27:250-261.
10. Chaturvedi R.K., Beal M.F. PPAR: a therapeutic target in Parkinson's disease. Journal of Neurochemistry 2008, 106:506-518.
11. Chung R.S., Penkowa M., Dittmann J., King C.E., Bartlett C., Asmussen J.W., Hidalgo J., Carrasco J., Leung Y.K., Walker A.K., Fung S.J., Dunlop S.A., Fitzgerald M., Beazley L.D., Chuah M.I., Vickers J.C., West A.K. Redefining the role of metallothionein within the injured brain: extracellular metallothioneins play an important role in the astrocyte-neuron response to injury. Journal of Biological Chemistry 2008, 283:15349-15358.
12. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. European Journal of Neuroscience 2002, 15:991-998.
13. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. Journal of Neuroscience 2000, 20:558-567.
14. Cristiano L., Bernardo A., Cerù M.P. Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes. Journal of Neurocytology 2001, 30:671-683.
15. Cullingford T.E., Bhakoo K., Peuchen S., Dolphin C.T., Patel R., Clark J.B. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. Journal of Neurochemistry 1998, 70:1366-1375.
16. de Meira Santos Lima M., Braga Reksidler A., Marques Zanata S., Bueno Machado H., Tufik S., Vital M.A. Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Research 2006, 1101:117-125.
17. Dehmer T., Heneka M.T., Sastre M., Dichgans J., Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. Journal of Neurochemistry 2004, 88:494-501.
18. Dhir A., Naidu P.S., Kulkarni S.K. Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure 2007, 16:691-697.
19. Drew P.D., Xu J., Storer P.D., Chavis J.A., Racke M.K. Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochemistry International 2006, 49:183-189.
20. Endo T. Glycans and glycan-binding proteins in brain: galectin-1-induced expression of neurotrophic factors in astrocytes. Current Drug Targets 2005, 6:427-436.
21. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. Journal of Neurochemistry 2002, 81:1285-1297.
22. Gupta A., Dhir A., Kumar A., Kulkarni S.K. Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats. Pharmacology, Biochemistry, and Behavior 2009, 94:219-226.
23. Hanrott K., Murray T.K., Orfali Z., Ward M., Finlay C., O'Neill M.J., Wonnacott S. Differential activation of PKC delta in the substantia nigra of rats following striatal or nigral 6-hydroxydopamine lesions. European Journal of Neuroscience 2008, 27:1086-1096.
24. Heneka M.T., Landreth G.E., Hüll M. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nature Clinical Practice. Neurology 2007, 3:496-504.
25. Henning J., Strauss U., Wree A., Gimsa J., Rolfs A., Benecke R., Gimsa U. Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease. Neuroscience Research 2008, 62:246-253.
26. Hyong A., Jadhav V., Lee S., Tong W., Rowe J., Zhang J.H., Tang J. Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Research 2008, 1215:218-224.
27. Hunter R.L., Dragicevic N., Seifert K., Choi D.Y., Liu M., Kim H.C., Cass W.A., Sullivan P.G., Bing G. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. Journal of Neurochemistry 2007, 100:1375-1386.
28. Hunter R.L., Choi D.Y., Ross S.A., Bing G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neuroscience Letters 2008, 432:198-201.
29. Iczkiewicz J., Rose S., Jenner P. Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss. Experimental Neurology 2007, 207:95-106.
30. Kato H., Kurosaki R., Oki C., Araki T. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Research 2004, 1030:66-73.
31. Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Beal M.F. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Experimental Neurology 2005, 191:331-336.
32. Kim E.J., Kwon K.J., Park J.Y., Lee S.H., Moon C.H., Baik E.J. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Research 2002, 941:1-10.
33. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. New England Journal of Medicine 1998, 339:1044-1053.
34. Leung Y.K., Pankhurst M., Dunlop S.A., Ray S., Dittmann J., Eaton E.D., Palumaa P., Sillard R., Chuah M.I., West A.K., Chung R.S. Metallothionein induces a regenerative reactive astrocyte phenotype via JAK/STAT and RhoA signalling pathways. Experimental Neurology 2010, 221:98-106.
35. Liang X., Wu L., Wang Q., Hand T., Bilak M., McCullough L., Andreasson K. Function of COX-2 and prostaglandins in neurological disease. Journal of Molecular Neuroscience 2007, 33:94-99.
36. Luo Y., Yin W., Signore A.P., Zhang F., Hong Z., Wang S., Graham S.H., Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Journal of Neurochemistry 2006, 97:435-448.
37. Marinova-Mutafchieva L., Sadeghian M., Broom L., Davis J.B., Medhurst A.D., Dexter D.T. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. Journal of Neurochemistry 2009, 110:966-975.
38. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
39. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Movement Disorders 2008, 23:474-483.
40. McGeer P.L., Schwab C., Parent A., Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Annals of Neurology 2003, 54:599-604.
41. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. Journal of Neuropathology and Experimental Neurology 2004, 63:901-910.
42. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neuroscience Letters 1994, 165:208-210.
43. Moore A.E., Cicchetti F., Hennen J., Isacson O. Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat. Experimental Neurology 2001, 171:363-376.
44. Moreno S., Farioli-Vecchioli S., Cerù M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004, 123:131-145.
45. Mori A., Ohashi S., Nakai M., Moriizumi T., Mitsumoto Y. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neuroscience Research 2005, 51:265-274.
46. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, San Diego.
47. Quinn L.P., Crook B., Hows M.E., Vidgeon-Hart M., Chapman H., Upton N., Medhurst A.D., Virley D.J. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. British Journal of Pharmacology 2008, 154:226-233.
48. Ridet J.L., Malhotra S.K., Privat A., Gage F.H. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neuroscience 1997, 20:570-577.
49. Rogers J., Mastroeni D., Leonard B., Joyce J., Grover A. Neuroinflammation in Alzheimer's disease and Parkinson's disease are microglia pathogenic in either disorder?. International Review of Neurobiology 2007, 82:235-246.
50. Rosenblad C., Kirik D., Björklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Experimental Neurology 2000, 161:503-516.
51. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. The European Journal of Neuroscience 2009, 29:954-963.
52. Sofroniew M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neuroscience 2009, 32:638-647.
53. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathologica 2010, 119:7-35.
54. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., O'Callaghan J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB Journal 2002, 16:1474-1476.
55. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393:790-793.
56. Stoll G., Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Progress in Neurobiology 1999, 58:233-247.
57. Streit W.J., Conde J.R., Fendrick S.E., Flanary B.E., Mariani C.L. Role of microglia in the central nervous system's immune response. Neurological Research 2005, 27:685-691.
58. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:5473-5478.
59. van Domburg P.H., Ten Donkelaar H.H. The human substantia nigra and ventrak tegmental area. A neuroanatomical study with notes on aging and aging disease. Advances in Anatomy, Embryology, and Cell Biology 1991, 121:1-132.
60. Vila M., Jackson-Lewis V., Guégan C., Wu D.C., Teismann P., Choi D.K., Tieu K., Przedborski S. The role of glial cells in Parkinson's disease. Current Opinion in Neurology 2001, 14:483-489.
61. Walsh S., Finn D.P., Dowd E. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience 2011, 175:251-261.
62. Watanabe Y., Kato H., Araki T. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease. Metabolic Brain Disease 2008, 23:51-69.
63. Woster A.P., Combs C.K. Differential ability of a thiazolidinedione PPARgamma agonist to attenuate cytokine secretion in primary microglia and macrophage-like cells. Journal of Neurochemistry 2007, 103:67-76.
64. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. Journal of Neuroscience 2003, 23:7504-7509.